FDA has issued warning to Reviva
Labs, a Jersey based cosmetic re-packer and labeler, as well as a re-labeler of
over-the-counter (OTC) drug products, for creating misleading projections. FDA
inspected the facility of the firm and served notice to remove the misleading
labels on products and onsite contents.
FDA objected to using terms like : “reduces
blemish-causing bacteria”, “reduce inflammation”, “reduces blemish-causing
bacteria..”, “effective treatment for brown spots and other skin discolorations”,
“diminish dark spots” and many more. This
unapproved language on labels creates the impression that these cosmetic products
are very effective like drugs, whereas FDA has strict procedure before any
product can be labelled and sold as drug, and it approves a new drug only on
the basis of scientific data and information demonstrating that the drug is
safe and effective as per claim.
FDA has been vigilant to ensure that
cosmetic manufacturers do not market their products unethically by promoting
them like drugs. On the other hand, the
cosmetic companies have been trying to circumvent FDA regulations, and promote
their products as “new formulae”, “new treatment”, and so on. This is
particularly rampant among online suppliers of cosmetic items.
The other unfair practice of many
players is that they do not display the ingredients on the labels, though making
all kinds of unverifiable claims, and marketing them with attractive glamorous
marketing campaigns.
Although FDA has asked Reviva Labs
to “take prompt action to correct the violations” failing which may result in
legal action, the consumers also need to exercise caution, and satisfy
themselves of the reliability and efficacy of the cosmetics they choose to buy.
No comments:
Post a Comment